89bio, Inc.
142 Sansome Street
Second Floor
San Francisco, CA 94104
United States
415 432 9270
https://www.89bio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 70
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Rohan Palekar | CEO & Director | 1.06M | 無 | 1966 |
| Mr. Quoc Le-Nguyen | Chief Technical Operations Officer & Head of Quality | 702.87k | 無 | 1968 |
| Dr. Harry Mansbach M.D. | Chief Medical Officer | 732.87k | 無 | 1965 |
| Mr. Ryan Stephen Martins | Chief Financial Officer | 無 | 無 | 1979 |
| Mr. Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer | 無 | 無 | 1966 |
| Ms. Annie J. Chang M.B.A. | VP of Investor Relations & Corporate Communications | 無 | 無 | 無 |
| Ms. Amanda Kurihara | Vice President of People & Culture | 無 | 無 | 無 |
| Ms. Yun Bai Ph.D. | VP and Head of Chemistry, Manufacturing & Controls ( CMC ) | 無 | 無 | 無 |
| Ms. Melissa Abel | Senior Vice President of Commercial Strategy | 無 | 無 | 無 |
| Mr. Paul Shin | Senior Vice President of R&D Operations | 無 | 無 | 無 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
公司管治
截至 2024年4月1日 止，89bio, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：6；董事會：7；股東權利：9；現金賠償：8。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
